Zafgen has debuted its IPO after pricing its 6 million shares at $16 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “ZFGN.” Leerink Partners and Cowen and Company are the lead underwriters. Based in Cambridge, Mass., Zafgen is a biopharmaceutical company focused on treating severely obese patients. Zafgen’s investors include RA Capital Management, Brookside Capital, Venrock and Alta Partners.
CAMBRIDGE, Mass., June 18, 2014 (GLOBE NEWSWIRE) — Zafgen, Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $16.00 per share, before underwriting discounts. All of the common stock is being offered by Zafgen. In addition, Zafgen has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Global Market on June 19, 2014 under the symbol “ZFGN.”
Leerink Partners LLC and Cowen and Company, LLC are acting as joint book-running managers of the offering. Canaccord Genuity Inc. and JMP Securities LLC are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 18, 2014. When available, copies of the final prospectus relating to the offering may be obtained by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 4814, or by email at [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, or by phone (631) 274-2806 / Fax (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.